Sam - the only thing that troubles me about this business is that 31 / 38 quarters their Cashflow from operations is negative. Not sure how then we come to a baseline value of the business at $1.50 - $2.50 / sh.
My research-agent after working on valuing it for an hour also noted:
- No recent open-market insider buying.
- Dilution: diluted share count nearly quadrupled since 2020 (33.7M→125.5M), funded entirely by equity issuance, zero buybacks/dividends ever (10-K FY2025 (https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm), Statements of Stockholders' Deficit). Relevant to whether the "$1.50/share ex-Anaphylm" and "$6.50" targets hold up as more capital gets raised before/at launch.
- Suboxone/Indivior legacy base is eroding fast: 73% of FY2025 revenue, company calls it a "sunsetting product," and computed roughly -9%/yr decline (10-K FY2025 Note 6 (https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm)) — relevant to whether "$1.50/share base business" is a stable floor or itself declining.
Found the past FDA outcomes part fascinating. Based on the research, it does seem more likely to be approved in 2027.
As you mentioned in a previous post, PTJ uses the 200 day MA as reference to the trend direction. AQST just wicked twice above it but closed below both times. Considering a starter position of 1% soon and adding with a firm close above it.
This investment proposal is compelling because it involves not merely a typical "story stock," but an asymmetric situation where the market appears to have equated a regulatory rejection with a failure of the drug itself.
Yet, available information suggests that the core objections did not concern the critical pharmacological or safety issues; furthermore, the subsequent rectification of usability problems now validates a key part of the original investment thesis.
The discrepancy between market expectations and the potential outcome is particularly attractive.
The market price seemingly continues to reflect a high probability of failure, whereas the historical reference group of comparable cases identified by the author demonstrates a significantly higher success rate, though this self-compiled sample should be viewed strictly as a hypothesis rather than a statistically robust 80% probability of FDA approval.
The real appeal lies in the combination of "limited downside risk from the existing business and massive potential upside from Anaphyl."
A successful approval process could redefine not only the revenue potential but also the valuation of the entire company.
At the same time, factors such as the FDA decision, competition from "neffy", commercialization, capital requirements, and the risk of dilution justify keeping the position size relatively small.
And therein lies the brilliant irony!
While the market remains fixated on the "Rejected" stamp, the astute and contrarian investor finds value in asking a far more mundane question:
Did the drug actually fail?
After all, the biggest mistake in the stock market is sometimes not taking a risky bet, but overlooking a potential mispricing simply because a headline is more convenient than doing the research.
Sam - the only thing that troubles me about this business is that 31 / 38 quarters their Cashflow from operations is negative. Not sure how then we come to a baseline value of the business at $1.50 - $2.50 / sh.
The financing was split between Oaktree debt ($55M of Oaktree's $150M facility is drawn, remainder gated on approval/milestone/mutual-consent) + RTW (not RXT) Investments LP ($75M, paid back as revenue sharing, capped at $225M): https://www.sec.gov/Archives/edgar/data/1398733/000139873326000042/aqst-20260630.htm
My research-agent after working on valuing it for an hour also noted:
- No recent open-market insider buying.
- Dilution: diluted share count nearly quadrupled since 2020 (33.7M→125.5M), funded entirely by equity issuance, zero buybacks/dividends ever (10-K FY2025 (https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm), Statements of Stockholders' Deficit). Relevant to whether the "$1.50/share ex-Anaphylm" and "$6.50" targets hold up as more capital gets raised before/at launch.
- Suboxone/Indivior legacy base is eroding fast: 73% of FY2025 revenue, company calls it a "sunsetting product," and computed roughly -9%/yr decline (10-K FY2025 Note 6 (https://www.sec.gov/Archives/edgar/data/1398733/000139873326000018/aqst-20251231.htm)) — relevant to whether "$1.50/share base business" is a stable floor or itself declining.
Sam, you are amazing. You do great research, and you do not make us suffer through AI speak in your writing. Thank you.
Found the past FDA outcomes part fascinating. Based on the research, it does seem more likely to be approved in 2027.
As you mentioned in a previous post, PTJ uses the 200 day MA as reference to the trend direction. AQST just wicked twice above it but closed below both times. Considering a starter position of 1% soon and adding with a firm close above it.
This investment proposal is compelling because it involves not merely a typical "story stock," but an asymmetric situation where the market appears to have equated a regulatory rejection with a failure of the drug itself.
Yet, available information suggests that the core objections did not concern the critical pharmacological or safety issues; furthermore, the subsequent rectification of usability problems now validates a key part of the original investment thesis.
The discrepancy between market expectations and the potential outcome is particularly attractive.
The market price seemingly continues to reflect a high probability of failure, whereas the historical reference group of comparable cases identified by the author demonstrates a significantly higher success rate, though this self-compiled sample should be viewed strictly as a hypothesis rather than a statistically robust 80% probability of FDA approval.
The real appeal lies in the combination of "limited downside risk from the existing business and massive potential upside from Anaphyl."
A successful approval process could redefine not only the revenue potential but also the valuation of the entire company.
At the same time, factors such as the FDA decision, competition from "neffy", commercialization, capital requirements, and the risk of dilution justify keeping the position size relatively small.
And therein lies the brilliant irony!
While the market remains fixated on the "Rejected" stamp, the astute and contrarian investor finds value in asking a far more mundane question:
Did the drug actually fail?
After all, the biggest mistake in the stock market is sometimes not taking a risky bet, but overlooking a potential mispricing simply because a headline is more convenient than doing the research.